These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36637820)

  • 1. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
    Caprioglio C; Ribaldi F; Visser LNC; Minguillon C; Collij LE; Grau-Rivera O; Zeyen P; Molinuevo JL; Gispert JD; Garibotto V; Moro C; Walker Z; Edison P; Demonet JF; Barkhof F; Scheltens P; Alves IL; Gismondi R; Farrar G; Stephens AW; Jessen F; Frisoni GB; Altomare D;
    JAMA Netw Open; 2023 Jan; 6(1):e2250921. PubMed ID: 36637820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial.
    Altomare D; Barkhof F; Caprioglio C; Collij LE; Scheltens P; Lopes Alves I; Bouwman F; Berkhof J; van Maurik IS; Garibotto V; Moro C; Delrieu J; Payoux P; Saint-Aubert L; Hitzel A; Molinuevo JL; Grau-Rivera O; Gispert JD; Drzezga A; Jessen F; Zeyen P; Nordberg A; Savitcheva I; Jelic V; Walker Z; Edison P; Demonet JF; Gismondi R; Farrar G; Stephens AW; Frisoni GB;
    JAMA Neurol; 2023 Jun; 80(6):548-557. PubMed ID: 37155177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease.
    Hönig M; Altomare D; Caprioglio C; Collij L; Barkhof F; Van Berckel B; Scheltens P; Farrar G; Battle MR; Theis H; Giehl K; Bischof GN; Garibotto V; Molinuevo JLL; Grau-Rivera O; Delrieu J; Payoux P; Demonet JF; Nordberg AK; Savitcheva I; Walker Z; Edison P; Stephens AW; Gismondi R; Jessen F; Buckley CJ; Gispert JD; Frisoni GB; Drzezga A;
    Neurology; 2024 Mar; 102(6):e208053. PubMed ID: 38377442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study.
    Wake T; Tabuchi H; Funaki K; Ito D; Yamagata B; Yoshizaki T; Nakahara T; Jinzaki M; Yoshimasu H; Tanahashi I; Shimazaki H; Mimura M
    Am J Alzheimers Dis Other Demen; 2020; 35():1533317520904551. PubMed ID: 32052640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
    Grill JD; Raman R; Ernstrom K; Sultzer DL; Burns JM; Donohue MC; Johnson KA; Aisen PS; Sperling RA; Karlawish J;
    JAMA Neurol; 2020 Dec; 77(12):1504-1513. PubMed ID: 32777010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline.
    Wake T; Tabuchi H; Funaki K; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M
    Int Psychogeriatr; 2018 May; 30(5):635-639. PubMed ID: 29094656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?
    Funaki K; Nakajima S; Noda Y; Wake T; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M; Tabuchi H
    Psychogeriatrics; 2019 Jul; 19(4):325-332. PubMed ID: 30688000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Amyloid Burden on Cognitive Decline over 2 years in Older Adults with Subjective Cognitive Decline: A Prospective Cohort Study.
    Hong YJ; Park JW; Lee SB; Kim SH; Kim Y; Ryu DW; Park KW; Yang DW
    Dement Geriatr Cogn Disord; 2021; 50(5):437-445. PubMed ID: 34736258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
    Lim YY; Maruff P; Getter C; Snyder PJ
    Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
    de Wilde A; van der Flier WM; Pelkmans W; Bouwman F; Verwer J; Groot C; van Buchem MM; Zwan M; Ossenkoppele R; Yaqub M; Kunneman M; Smets EMA; Barkhof F; Lammertsma AA; Stephens A; van Lier E; Biessels GJ; van Berckel BN; Scheltens P
    JAMA Neurol; 2018 Sep; 75(9):1062-1070. PubMed ID: 29889941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?
    Akinci M; Sánchez-Benavides G; Brugulat-Serrat A; Peña-Gómez C; Palpatzis E; Shekari M; Deulofeu C; Fuentes-Julian S; Salvadó G; González-de-Echávarri JM; Suárez-Calvet M; Minguillón C; Fauria K; Molinuevo JL; Gispert JD; Grau-Rivera O; Arenaza-Urquijo EM;
    Alzheimers Res Ther; 2022 Sep; 14(1):126. PubMed ID: 36068641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time.
    Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G
    Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study.
    Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW;
    Alzheimers Res Ther; 2023 Aug; 15(1):132. PubMed ID: 37550761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia.
    Nedelska Z; Schwarz CG; Lesnick TG; Boeve BF; Przybelski SA; Lowe VJ; Kremers WK; Gunter JL; Senjem ML; Graff-Radford J; Ferman TJ; Fields JA; Knopman DS; Petersen RC; Jack CR; Kantarci K
    JAMA Netw Open; 2019 Dec; 2(12):e1916439. PubMed ID: 31790563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
    Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
    JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective cognitive complaints at age 70: associations with amyloid and mental health.
    Pavisic IM; Lu K; Keuss SE; James SN; Lane CA; Parker TD; Keshavan A; Buchanan SM; Murray-Smith H; Cash DM; Coath W; Wong A; Fox NC; Crutch SJ; Richards M; Schott JM
    J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1215-1221. PubMed ID: 34035132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.